alpelisib
Kura Oncology Prices $150M Private Placement
The financing will support Kura's ongoing R&D activities, including a Phase II trial of its menin inhibitor ziftomenib.
Relay Therapeutics' Early Data on Selective PIK3Cα Inhibitor Suggest Promising Tolerability
At AACR, researchers presented preliminary data from the Phase I ReDiscover trial, which suggested RLY-2608 could have a better safety profile than Novartis' Piqray.
NICE Recommends Novartis' Piqray, Gilead's Trodelvy for Certain Breast Cancer Patients in England
The institute was able to come to an agreement with the drugmakers to provide these therapies at an undisclosed, discounted price.
MSK to Launch Trial of T-Cell Receptor Therapy Targeting Common Neoantigen With Pharma Partner
Premium
The therapy, which could potentially have tissue-agnostic use, is designed to target a public neoantigen from a mutation in the oncogenic driver gene PIK3CA.
NICE Recommends Against Piqray Combo for PIK3CA-Mutated Metastatic Breast Cancer
The committee said it saw no direct evidence in favor of Piqray-fulvestrant when comparing it against standard treatments and found the cost-effectiveness estimates too high.